A tablet formulation of DDAVP (desmopressin acetate) has been approved for managing primary nocturnal enuresis in patients age six and over. DDAVP is a synthetic form of vasopressin that has been available in nasal spray since 1989. Vasopressin regulates water balance and urine production.
The Desmopressin Acetate (DDAVP) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.